PlainPharmaWatch

CMS Open Payments · Program Year 2024

Melinta Therapeutics, LLC

Melinta Therapeutics, LLC reported $976,591.84 in payments to 4,777 physicians and teaching hospitals across 4,839 transactions.

See the rankings → How this is sourced
$976.6K
Total payments
4,839
Transactions
4,777
Recipients
−$96.3K
General Payments vs PY2023

Melinta Therapeutics, LLC reported $976,591.84 in payments to 4,777 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #625 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $204.44 per recipient across 6 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Melinta Therapeutics, LLC pairs above-median payment volume with an unusually diversified payment pattern across a wide recipient base.

#625
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
6
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Melinta Therapeutics, LLC's CMS-reported General Payments decreased by $96.3K (−14.4%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: MELINTA THERAPEUTICS, LLCPY2023: MELINTA THERAPEUTICS, LLCPY2024: Melinta Therapeutics, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$670.0KPY2024$573.7K
PY2023
$669,976.24
PY2024
$573,660.01

How Melinta Therapeutics, LLC ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Melinta Therapeutics, LLC's total vs. every reporting company

CMS Open Payments, Program Year 2024

$976,592 Top 32% higher than 68% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Melinta Therapeutics, LLC

Averaging $201.82 per transaction and $204.44 per recipient, Melinta Therapeutics, LLC's Program Year 2024 total comes to $976,591.84 across 4,839 transactions and 4,777 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #625 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $233.3K, accounting for 23.9% of the company's reported total and 116 transactions.

General Payment Breakdown by Type

Melinta Therapeutics, LLC made 6 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $233.3K, 23.9% of the company's reported total.

How Melinta Therapeutics, LLC divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$233.3K2. Food and Beverage$135.3K3. Consulting Fee$108.1K4. Travel and Lodging$39.0K5. Education$38.5K6. Grant$19.5K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $233.3K 116
Food and Beverage $135.3K 4,468
Consulting Fee $108.1K 37
Travel and Lodging $39.0K 124
Education $38.5K 31
Grant $19.5K 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $189,410.08 (33.0%) of $573,660.01 in this company's General Payments records across 2,080 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Melinta Therapeutics, LLC

The five named recipients with the highest reported General Payments from this company

Amar Safdar$44.2KJuan D Diaz$43.9KMarya D. Zilberberg$41.5KJose A Vazquez$37.8KHector Brunet Rodriguez$22.1K
  1. 1

    Amar Safdar

    $44,174.90 across 45 reported transactions

  2. 2

    Juan D Diaz

    $43,883.49 across 56 reported transactions

  3. 3

    Marya D. Zilberberg

    $41,500.00 across 1 reported transactions

  4. 4

    Jose A Vazquez

    $37,785.06 across 47 reported transactions

  5. 5

    Hector Brunet Rodriguez

    $22,066.63 across 29 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $201.82. Average per recipient: $204.44.

Total Amount

$976,591.84

Avg per Transaction

$201.82

Avg per Recipient

$204.44

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Melinta Therapeutics, LLC Share

0.0%

#625 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Melinta Therapeutics, LLC

pharmaand GmbH

$976.9K 57 recipients

US Endoscopy

$971.8K 103 recipients

InspireMD Ltd

$983.4K 64 recipients

Topcon Healthcare, Inc.

$985.2K 688 recipients

Ortho Dermatologics, a division of Bausch Health US, LLC

$999.3K 13,977 recipients

Hikma Pharmaceuticals USA

$953.3K 3,664 recipients

Frequently Asked Questions

How much did Melinta Therapeutics, LLC pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $976,591.84 from Melinta Therapeutics, LLC to physicians and hospitals across 4,839 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Melinta Therapeutics, LLC? ▾
4,777 physicians and teaching hospitals received payments from Melinta Therapeutics, LLC in 2024, averaging $204.44 per recipient.
What types of payments did Melinta Therapeutics, LLC make? ▾
General payments from Melinta Therapeutics, LLC span 6 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Compensation for Services Other Than Consulting" at $233.3K, representing 23.9% of the company's reported total.
How does Melinta Therapeutics, LLC rank among pharmaceutical companies? ▾
By total payment amount, Melinta Therapeutics, LLC sits at #625 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Melinta Therapeutics, LLC? ▾
The average transaction from Melinta Therapeutics, LLC was $201.82 in 2024. The company made 4,839 total transactions to 4,777 recipients.
Where does the payment data for Melinta Therapeutics, LLC come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Melinta Therapeutics, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.